These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 7359321)

  • 21. Direct analysis in real time--high resolution mass spectrometry as a valuable tool for the pharmaceutical drug development.
    Srbek J; Klejdus B; Douša M; Břicháč J; Stasiak P; Reitmajer J; Nováková L
    Talanta; 2014 Dec; 130():518-26. PubMed ID: 25159441
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmaceutical impurities and degradation products: uses and applications of NMR techniques.
    Maggio RM; Calvo NL; Vignaduzzo SE; Kaufman TS
    J Pharm Biomed Anal; 2014 Dec; 101():102-22. PubMed ID: 24853620
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Estimation of impurity profiles of drugs and related materials. 20. Methodological problems in the identification and determination of organic impurities].
    Görög S
    Acta Pharm Hung; 2000; 70(3-6):131-7. PubMed ID: 11379019
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A double-blind randomized placebo controlled gastroscopic study to compare the effects of indomethacin capsules and indomethacin suppositories on the gastric mucosa of human volunteers.
    Lanza FL; Umbenhauer ER; Nelson RS; Rack MF; Daurio CP; White LA
    J Rheumatol; 1982; 9(3):415-9. PubMed ID: 6750118
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Quantitative thin-layer chromatographic method of analysis of azithromycin in pure and capsule forms.
    Khedr A; Sheha M
    J Chromatogr Sci; 2003 Jan; 41(1):10-6. PubMed ID: 12597590
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Isolation and characterization of process-related impurities and degradation products in larotaxel.
    Che X; Shen L; Xu H; Liu K
    J Pharm Biomed Anal; 2011 Jul; 55(5):1190-6. PubMed ID: 21530132
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of multiple impurities in a pharmaceutical matrix using preparative gas chromatography and computer-assisted structure elucidation.
    Codina A; Ryan RW; Joyce R; Richards DS
    Anal Chem; 2010 Nov; 82(21):9127-33. PubMed ID: 20942391
    [TBL] [Abstract][Full Text] [Related]  

  • 28. All on one high-performance thin-layer chromatography plate: solvent-free nanomole-scaled on-surface synthesis, workup and online high-resolution mass spectrometry for elucidation of two new degradation products in an ifosfamide formulation.
    Yüce I; Morlock GE
    J Chromatogr A; 2018 Oct; 1572():145-151. PubMed ID: 30166113
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of reaction products between drug substances and excipients by HPLC-SPE-NMR: ester and amide formation between citric acid and 5-aminosalicylic acid.
    Larsen J; Staerk D; Cornett C; Hansen SH; Jaroszewski JW
    J Pharm Biomed Anal; 2009 Apr; 49(3):839-42. PubMed ID: 19185440
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Feasibility of the Ph.Eur. flow-through cell for dissolution testing of the compounded rectal suppositories containing indomethacin or sodium diclofenac.
    Woyczikowski B; Szulc J; Sznitowska M; Janicki S; Pilichowski J; Urbańska A
    Acta Pol Pharm; 2003; 60(3):169-72. PubMed ID: 14556483
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Thin-layer chromatography-nuclear magnetic resonance spectroscopy - a versatile tool for pharmaceutical and natural products analysisa.
    Gössi A; Scherer U; Schlotterbeck G
    Chimia (Aarau); 2012; 66(5):347-9. PubMed ID: 22867552
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An Elemental Impurities Excipient Database: A Viable Tool for ICH Q3D Drug Product Risk Assessment.
    Boetzel R; Ceszlak A; Day C; Drumm P; Gil Bejar J; Glennon J; Harris L; Heghes CI; Horga R; Jacobs PL; Keurentjes WJTM; King F; Lee CW; Lewen N; Marchant CA; Maris FA; Nye W; Powell S; Rockstroh H; Rutter L; Schweitzer M; Shannon E; Smallshaw L; Teasdale A; Thompson S; Wilkinson D
    J Pharm Sci; 2018 Sep; 107(9):2335-2340. PubMed ID: 29679706
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Indomethacin sustained-release suppositories containing sugar ester.
    Nakajima T; Takashima Y; Furuya A; Ozawa Y; Kawashima Y
    Chem Pharm Bull (Tokyo); 1990 Apr; 38(4):1027-31. PubMed ID: 2379274
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Improvement of dissolution and absorption characteristics of indomethacin by water-soluble alpha-cyclodextrin-epichlorohydrin polymer.
    Uekama K; Udo K; Irie T; Yoshida A; Otagiri M; Seo H; Tsuruoka M
    Acta Pharm Suec; 1987; 24(1):27-36. PubMed ID: 3618246
    [No Abstract]   [Full Text] [Related]  

  • 35. Isolation, identification, and synthesis of two oxidative degradation products of olanzapine (LY170053) in solid oral formulations.
    Baertschi SW; Brunner H; Bunnell CA; Cooke GG; Diseroad B; Dorman DE; Jansen PJ; Kemp CA; Maple SR; McCune KA; Speakman JL
    J Pharm Sci; 2008 Feb; 97(2):883-92. PubMed ID: 17879984
    [TBL] [Abstract][Full Text] [Related]  

  • 36. DISSOLUTION AND COMPATIBILITY STUDY OF BINARY AND TERNARY INTERACTIVE MIXTURES OF INDOMETHACIN: COMPARISON WITH COMMERCIALLY AVAILABLE CAPSULES.
    Maswadeh HM
    Acta Pol Pharm; 2016; 73(3):739-48. PubMed ID: 27476292
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Validated chromatographic methods for simultaneous determination of tolfenamic acid and its major impurities.
    Abdelwahab NS; Ali NW; Zaki MM; Abdelkawy M
    J Chromatogr Sci; 2015 Apr; 53(4):484-91. PubMed ID: 25016532
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Suppositories containing cyclodextrin complexes. Part 2: Dissolution and absorption studies.
    Szente L; Apostol I; Gerlóczy A; Szejtli J
    Pharmazie; 1985 Jun; 40(6):406-7. PubMed ID: 4034649
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Control and analysis of alkyl and benzyl halides and other related reactive organohalides as potential genotoxic impurities in active pharmaceutical ingredients (APIs).
    Elder DP; Lipczynski AM; Teasdale A
    J Pharm Biomed Anal; 2008 Nov; 48(3):497-507. PubMed ID: 18657926
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Isolation and characterisation of degradant impurities in dipyridamole formulation.
    Venkata Subbaiah B; Sree Ganesh KK; Vamsi Krishna G; Vyas K; Vasu Dev R; Subramanyam Reddy K
    J Pharm Biomed Anal; 2012 Mar; 61():256-64. PubMed ID: 22206889
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.